News Sentiment

MENS sentiment intelligence

Jyong Biotech Ltd. Ordinary Shares news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 43 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.21 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

88/100 classification confidence.

Company focus 35

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-0.5% over one week, +39.9% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Doctor shares the ‘most troubling trend’ in men’s health — and why biohacking is to blame

Market Reaction

Balanced read

56/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 88/100 classification
One-week reaction -0.5% Price digesting
Trend fit Trend inactive 39.9% over four weeks
Fair value -88.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 26
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 35
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 6
TradingKey 6
GlobeNewswire 5
TradingView 5
Stock Titan 4
simplywall.st 3
Pluang 2
New York Post 1

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 8
Capital return 1
Balance sheet 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-43 of 43
GlobeNewswire Direct company coverage

Jyong Biotech Updates Market Access Strategy for Innovative

Jyong Biotech announced advancements in its market access strategies for innovative plant-based drugs, Botreso and PCP, based on their clinical efficacy and competitive advantages. The company highlights the excellent safety profile, potential for prostate cancer prevention, and

Tone
Positive 73/100
Event
Market update
Published
29 Apr 2026 01:09
Source
GlobeNewswire
Stock Titan Direct company coverage

Two plant-based prostate drug candidates move toward broader markets

Jyong Biotech has advanced market access strategies for its botanical drugs Botreso and PCP, emphasizing their clinical efficacy, safety, and competitive advantages in manufacturing. Both drugs aim to address prostate health, with Botreso completing Phase III trials and PCP finis

Tone
Positive 63/100
Event
Market update
Published
28 Apr 2026 12:38
Source
Stock Titan
MarketBeat Direct company coverage

Short Interest in Jyong Biotech Ltd. (NASDAQ:MENS) Decreases By 43.2%

Short interest in Jyong Biotech Ltd. (NASDAQ:MENS) significantly decreased by 43.2% in April, totaling 133,023 shares, which represents about 0.2% of its outstanding shares. This decline brings the short-interest ratio to approximately 1.0 days. Despite institutional investors li

Tone
Neutral 50/100
Event
Market update
Published
28 Apr 2026 01:39
Source
MarketBeat
Zacks Investment Research Direct company coverage

Should I buy Jyong Biotech Ltd. (MENS)

Tone
Positive 66/100
Event
Market update
Published
31 Jul 2025 20:22
Source
Zacks Investment Research